Imaging from weeks 13 and 17 after presentation, before and after bevacizumab therapy. (A) Color fundus image demonstrating persistence of the subfoveal retinal pigment epithelial detachment (PED) 13 weeks after presentation. The line indicates the location of the swept-source optical coherence tomography angiography (SS-OCTA) B-scan in (B). (B) SS-OCTA cross-sectional B-scan with the boundaries depicted for the choriocapillaris flow and structural en face images (C) En face flow image of the choriocapillaris 13 weeks after presentation showing a persistent decrease in flow underlying the inflammatory PED. (D) En face structural image of the choriocapillaris showing good signal intensity. (E) Color fundus image demonstrating persistence of the foveal lesion 4 weeks later, after an injection of intravitreal bevacizumab. The line indicates the location of the subsequent SS-OCTA B-scan in (F). (F) SS-OCTA cross-sectional B-scan with segmentation boundaries for the choriocapillaris. (G) En face flow image of the choriocapillaris with a persistent decrease in flow underlying the PED. (H) En face structural image of the choriocapillaris showing a good signal in the area of decreased choriocapillaris flow underlying the lesion.